Bagsværd, Denmark, 8 October 2020 – Novo Nordisk today announced that the full-year sales and operating profit outlook at constant exchange rates (CER) has been raised.
See original here:
Novo Nordisk raises sales and operating profit outlook for 2020
With the new contract, PRA will assist Biomedical Advanced Research and Development Authority (BARDA) in the development of medical countermeasures for public health
Read the original post:
PRA Health Sciences selected by BARDA to be a member of its exclusive Clinical Studies Network
SALINAS, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Indus Holdings, Inc. ("Indus” or the “Company”) (CSE:INDS; OTCQX: INDXF), a leading, vertically-integrated, California-focused cannabis company, announced preliminary unaudited revenue and adjusted EBITDA for the third quarter ended September 30, 2020. All figures stated are in US Dollars. Based on a preliminary review, the Company currently anticipates:
The rest is here:
Indus Holdings, Inc. Pre-Announces Record Q3 2020 Revenues in Excess of $14 Million, ~15% EBITDA Margins, and Positive Operating Income
BOSTON, Oct. 08, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead asset, mavorixafor, for the treatment of adult patients with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene.
Read the original post:
X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM Syndrome
Management and Board Have Funded More than $11M to Support Growth Management and Board Have Funded More than $11M to Support Growth
Originally posted here:
Better Choice Announces Closing of Expanded Series F Financing and Acceleration of Asian Expansion
VALENCIA, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- SetPoint Medical, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel bioelectronic device for patients with rheumatoid arthritis (RA) who have incomplete response to, or are intolerant to multiple biologic drugs. The Company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases, and is initially focused on the treatment of RA as a potentially efficacious, yet less immunosuppressive option.
Read the original here:
SetPoint Medical Receives FDA Breakthrough Device Designation for its Novel Bioelectronic Platform
MORRISVILLE, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it was awarded the Society for Clinical Research Sites (SCRS) Eagle Award, sweeping the CRO category for the fourth consecutive year. Presented at SCRS’s Global Site Solutions Summit, the award recognizes the CRO that best exemplifies a site-focused approach to clinical trial management, demonstrating outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships.
Read the original here:
Syneos Health Wins Society for Clinical Research Sites Eagle Award for Fourth Consecutive Year
Application of ImmTOR™ plus IGAN’s IgA protease to target immunoglobulin A (IgA) deposition, the critical event leading to IgA Nephropathy (IgAN)
Go here to see the original:
Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in...
·BYFAVO expected to be commercially available in the US before the end of the year This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
See the article here:
Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch...
? Clear Development Path Forward for XRx-101 ? ? Clear Development Path Forward for XRx-101 ?
Excerpt from:
XORTX Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury